ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Inclusion Criteria: * Informed Consent form signed by the participant or participant's legal representative; if the participant was under the age of 18 but capable of providing assent, signed assent from the participant. * Participant (or caretaker) must have been willing to comply with all protocol requirements. * Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. * Participant must have had 1 target wound (size 10 to 50 cm\^2) at study entry. * Participants 1 month and older. * Target wound must have been present for at least 21 days. Exclusion Criteria: * Participants who did not meet the entry criteria outlined above. * Selected target wound did not have clinical evidence of local infection. * Use of any investigational drug within the 30 days before enrollment. * Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment. * Use of systemic or topical steroidal therapy within the 30 days before enrollment. (Inhaled steroids and ophthalmic drops containing steroids were allowed). * Use of systemic antibiotics within the 7 days before enrollment. * Current or former malignancy. * Arterial or venous disorder resulting in ulcerated lesions. * Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at screening and every 30 days until the final visit for female participants of childbearing potential). * Females of childbearing potential who were not abstinent and not practicing a medically acceptable…